- Home
- CNMD vs NVAX Comparison
CNMD vs NVAX Comparison
Compare CNMD & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNMD
- NVAX
- Stock Information
- Founded
- CNMD 1970
- NVAX 1987
- Country
- CNMD United States
- NVAX United States
- Employees
- CNMD N/A
- NVAX N/A
- Industry
- CNMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNMD Health Care
- NVAX Health Care
- Exchange
- CNMD Nasdaq
- NVAX Nasdaq
- Market Cap
- CNMD 1.7B
- NVAX 1.3B
- IPO Year
- CNMD 1987
- NVAX 1995
- Fundamental
- Price
- CNMD $54.09
- NVAX $6.60
- Analyst Decision
- CNMD Hold
- NVAX Buy
- Analyst Count
- CNMD 5
- NVAX 5
- Target Price
- CNMD $62.20
- NVAX $16.60
- AVG Volume (30 Days)
- CNMD 388.5K
- NVAX 5.5M
- Earning Date
- CNMD 07-30-2025
- NVAX 08-07-2025
- Dividend Yield
- CNMD 1.46%
- NVAX N/A
- EPS Growth
- CNMD 46.38
- NVAX N/A
- EPS
- CNMD 3.81
- NVAX 2.97
- Revenue
- CNMD $1,315,998,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- CNMD $6.27
- NVAX $56.85
- Revenue Next Year
- CNMD $5.62
- NVAX N/A
- P/E Ratio
- CNMD $14.38
- NVAX $2.22
- Revenue Growth
- CNMD 4.32
- NVAX 25.92
- 52 Week Low
- CNMD $46.00
- NVAX $5.01
- 52 Week High
- CNMD $78.19
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- CNMD 48.76
- NVAX 42.34
- Support Level
- CNMD $51.43
- NVAX $6.26
- Resistance Level
- CNMD $53.05
- NVAX $6.60
- Average True Range (ATR)
- CNMD 1.66
- NVAX 0.27
- MACD
- CNMD -0.06
- NVAX -0.06
- Stochastic Oscillator
- CNMD 37.73
- NVAX 15.94
About CNMD CONMED Corporation
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.